Kim Seung Cheol, Kim Min Kyung, Kim Yun Hwan, Ahn Sun-A, Kim Kyung-Hee, Kim Kun, Kim Won Ki, Lee Jun Hwa, Cho Jae Youl, Yoo Byong Chul
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ewha Woman's University Mokdong Hospital, Ewha Woman's University School of Medicine, Seoul 158-710, Republic of Korea.
Colorectal Cancer Branch, Research Institute, National Cancer Center, Gyeonggi 410-769, Republic of Korea.
Oncol Lett. 2014 Aug;8(2):566-574. doi: 10.3892/ol.2014.2214. Epub 2014 Jun 3.
Ovarian cancer (OVC) is one of the most difficult types of cancer to detect in the early stages of its development. There have been numerous attempts to identify a biomarker for OVC; however, an accurate diagnostic marker has yet to be identified. The present study profiled OVC candidate metabolites from the serum to identify potential diagnostic markers for OVC. Data regarding low-mass ions (LMIs) in the serum were obtained using matrix-assisted laser desorption/ionization (MALDI)-time-of-flight analysis. MALDI-mass spectrometry (MS) analysis of each serum sample was repeated six times in order to reduce the likelihood of experimental errors. The intensity of the LMI mass peaks were normalized using total peak area sums. The normalized intensity of LMI was used in principal component analysis-discriminant analysis to differentiate between 142 patients with OVC and 100 healthy control participants. Liquid chromatography-MS/MS was used to identify the selected LMIs. Extracted ion chromatogram analysis was used to measure the relative quantity of candidate metabolites from the LMI mass peak areas. The concentration of common metabolites in the serum was determined using ELISA. The top 20 LMI mass peaks with a weigh factor over 0.05 were selected to distinguish between the patients with OVC and the controls. Among the LMIs, two with 184.05 and 496.30 m/z were identified as L-homocysteic acid (HCA) and lysophosphatidylcholine (LPC) (16:0), respectively. The relative quantity of LPC (16:0) was found to be decreased in the OVC serum (P=0.05), while the quantity of HCA was observed to be significantly higher in the OVC serum (P<0.001). HCA was not detected in 59 cases out of the 63 control participants; however, the majority of the cases of OVC (16/25) exhibited significantly higher quantities of HCA. When the cutoff was 10 nmol/ml, the sensitivity and specificity of HCA were 64.0 and 96.9%, respectively. The level of LPC (16:0) was significantly correlated with tumor grade (P=0.045). HCA and LPC (16:0) showed correlation with stage and tumor histology, but the limited sample size resulted in a lack of statistical significance. The findings of the present study suggest that HCA may have potential to be a biomarker for OVC. The stratified screening including LPC (16:0) did not significantly increase the power for OVC screening; however, the present study showed that profiling LMIs in serum may be useful for identifying candidate metabolites for OVC screening.
卵巢癌(OVC)是在其发展早期最难检测的癌症类型之一。已经进行了许多尝试来鉴定卵巢癌的生物标志物;然而,尚未鉴定出准确的诊断标志物。本研究对血清中的卵巢癌候选代谢物进行了分析,以确定卵巢癌的潜在诊断标志物。使用基质辅助激光解吸/电离(MALDI)-飞行时间分析获得血清中低质量离子(LMI)的数据。对每个血清样本进行MALDI-质谱(MS)分析6次,以降低实验误差的可能性。LMI质量峰的强度使用总峰面积总和进行归一化。LMI的归一化强度用于主成分分析-判别分析,以区分142例卵巢癌患者和100名健康对照参与者。使用液相色谱-MS/MS鉴定选定的LMI。提取离子色谱图分析用于从LMI质量峰面积测量候选代谢物的相对量。使用酶联免疫吸附测定(ELISA)测定血清中常见代谢物的浓度。选择权重因子超过0.05的前20个LMI质量峰来区分卵巢癌患者和对照。在LMI中,两个分别为184.05和496.30 m/z的被鉴定为L-高半胱氨酸(HCA)和溶血磷脂酰胆碱(LPC)(16:0)。发现LPC(16:0)在卵巢癌血清中的相对量降低(P = 0.05),而观察到HCA在卵巢癌血清中的量显著更高(P < 0.001)。在63名对照参与者中的59例中未检测到HCA;然而,大多数卵巢癌病例(16/25)表现出显著更高的HCA量。当临界值为10 nmol/ml时,HCA的敏感性和特异性分别为64.0%和96.9%。LPC(16:0)的水平与肿瘤分级显著相关(P = 0.045)。HCA和LPC(16:0)与分期和肿瘤组织学相关,但样本量有限导致缺乏统计学意义。本研究结果表明HCA可能有潜力成为卵巢癌的生物标志物。包括LPC(16:0)的分层筛查并未显著提高卵巢癌筛查能力;然而,本研究表明分析血清中的LMI可能有助于鉴定卵巢癌筛查的候选代谢物。